NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...

The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. The Food and Drug Administration has ...

A validation of the observer-reported outcome of the Growth Hormone Deficiency-Child Impact Measure found it valid and reliable to understand the impact of treatment with growth hormone therapy.

SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new ...

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the ...

MISSISSAUGA, ON, Oct. 15, 2025 /CNW/ - Novo Nordisk has announced that Sogroya ® (somapacitan injection) is now commercially available in Canada. Sogroya ® is indicated for the long-term treatment of ...

What Treatment Options are Available? Once a diagnosis is confirmed, children with PGHD often work closely with an endocrinologist to develop a treatment plan that includes growth hormone replacement ...

Growth hormone (GH) therapy has evolved rapidly since the introduction of recombinant human GH (rhGH). The increase in the availability and safety of GH therapy has also increased the number of US ...

The primary sign of growth hormone deficiency in children is short stature. Adults may have decreased muscle mass and increased body fat, as well as other problems such as heart disease and depression ...

Sogroya is administered by subcutaneous injection one time each week. The Food and Drug Administration (FDA) has approved Sogroya® (somapacitan-beco; Novo Nordisk) injection for the replacement of ...

The MarketWatch News Department was not involved in the creation of this content. The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of ...